CLOSE

Dialog Box

Loading...

Clinical Trials 

Clinical trials are an essential part of the development of new treatments and help to improve the diagnosis, treatment and management of people with cancer.

RCA provides information about clinical trial registries and individual clinical trials with the hope that it assists you to be informed about what clinical trials are available. However, RCA is not responsible for the content or maintenance of these sites or specific clinical trial information. We will endeavor to keep this information up to date but the reader is ultimately responsible to check the accuracy of this information.

RCA neither recommends nor endorses any clinical trials. Patients are encouraged to complete their own research into any clinical trials and possible effects and impacts to their health as a result of such trials. It is the patient’s responsibility, in consultation with their medical professional, to determine whether they wish to take part in such trials.
 
Before you consider participation in any clinical trial you should seek advice from your medical professional. 

Clinical Trial Registries

Clinical trial registries allow you to find clinical trials in Australia. A registry is defined as an organisation or website that either:

  • Lists clinical trials being conducted (or that have recently been conducted) in Australia (or internationally, including Australia)
  • Provides a mechanism for patients or others to register their interest in participating in an Australian clinical trial
  • Provides a link between potential participants and Australian clinical trials.

For Clinical Trial Registries please visit australianclinicaltrials.gov.au.

Other clinical trial registries can be found by visiting these links:

http://www.australiancancertrials.gov.au/
http://www.cancervic.org.au/trials/
http://www.cancertrialsaustralia.com/
http://www.anzctr.org.au/

Other Clinical Trials

From time to time RCA is approached by clinicians who are involved with a clinical trial to share relevant information with the patient community. Details of these trials with contact information are below.

Trial Name: The Cancer Molecular Screening and Therapeutics (MoST) Program-Screening. (ACTRN12616000908437)
Location: NHMRC Clinical Trials Centre, Level 6, Chris O'Brien Lifehouse, 119–143 Missenden Road, Camperdown NSW 2050
Description:
This study is a collaboration between the Garvan Institute of Medical Research, the Kinghorn Cancer Centre, Sydney Catalyst and the NHMRC Clinical Trials Centre, University of Sydney. The study is currently open at St Vincent’s Hospital in Darlinghurst, and will soon open at Chris O’Brien Lifehouse and St George’s Hospital in Sydney.
      The study is led by Professor David Thomas (Garvan Institute of Medical Research, The Kinghorn Cancer Centre) and Professor John Simes (NHMRC Clinical Trials Centre).
      The explosion in genomic capacity presents the opportunity to molecularly phenotype cancers in unprecedented detail. Genomic screening tools are increasingly used to guide therapeutic decisions for individual patients, yielding the notion of ‘precision’ medicine.  
      The MoST Study uses novel genomics and other molecular assays for therapeutic targets, to identify ‘actionable’ mutations for patients with advanced cancers of any kind, but with a particular focus on rare cancers. The MoST then offers multiple, parallel, signal-seeking trials of novel drugs to patents in whom an ‘actionable’ target is found.
Contact:
For more details contact most@ctc.usyd.edu.au

Trial Name: PRISM: Precision Medicine for Children with Cancer (NCT03336931)
Location:   John Hunter Children's Hospital, Newcastle, NSW
                   Sydney Children's Hospital, Randwick, NSW
                   Lady Cilento Children's Hospital, Brisbane, QLD
                   Perth Children's Hospital, Perth, WA
Description: The program will involve the detailed laboratory analysis of each child’s unique cancer cells, to help identify the drugs most likely to kill their specific cancer. Scientists and doctors will then work collaboratively to identify and deliver the most effective treatment plan, specifically tailored to suit each child’s individual disease.
Contact: For more information visit http://www.zerochildhoodcancer.org.au/, call 1800 685 686, or email info@ccia.org.au

Trial Name: ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder (ACTRN12615001283561)
Location:    Bankstown-Lidcombe Hospital, Bankstown, NSW
                    Royal Brisbane & Womens Hospital, Herston, QLD
                    Flinders Medical Centre, Bedford Park, SA
                    Nepean Hospital, Kingswood, NSW
                    Calvary Mater Newcastle, Waratah, NSW
                    The Townsville Hospital, Douglas, QLD
                    Prince of Wales Hospital, Randwick, NSW
                    Princess Alexandra Hispital, Woolloongabba, QLD
                    Sir Charles Gairdner Hospital, Nedlands, WA
Description: The trial targets patients with histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after radical surgical therapy with macroscopically complete resection. Patients are treated with adjuvant chemotherapy with gemcitabine and cisplatin compared vs. capecitabine. It is hoped that the findings of this study will provide details on whether giving cisplatin and gemcitabine chemotherapy following surgery for cancer of the biliary tract is a safe and effective treatment to reduce the chance of disease progression and increase survival time and quality of life.
Contact: For more information contact ACTICCA-1 Trial Coordinator at acticca@ctc.usyd.edu.au

Trial Name: An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (NCT02632409)
Location:    Liverpool Hospital, Liverpool, New South Wales, Australia, 2170
                           Bavanthi Balakrishnar, 02 8738 5234      
                    Royal North Shore Hospital, St. Leonards, New South Wales, Australia, 2065
                           Alexander Guminski, 02 9463 1362      
                    Calvary Mater Newcastle, Waratah, New South Wales, Australia, 2298
                           Craig Gedye, 02 4014 3282      
                    Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia, 5112
                           Christopher Hocking, 08 8282 0833
                    St John of God Murdoch Hospital, Perth, Western Australia, Australia, 6150
                           Kynan Feeney, Site 08 9428 8556
Description: The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
Contact: For more information contact clinical.trials@bms.com

Trial Name: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (NCT02872116)
Location:    Gosford Hospital, Gosford, New South Wales, Australia, 2250
                           Craig Kukard, 02 4320 9854      
                    Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia, 4215
                            Andrew Hill, 07 5531 4811      
                    Royal Adelaide Hospital, Adelaide, South Australia, Australia, 5000
                            Nimit Singhal, 08 8222 0087      
                    Goulburn Valley Health, Shepparton, Victoria, Australia, 3630
                            Babak Tamjid, Site 03 5832 3778      
                    St John of God Murdoch Hospital, Perth, Western Australia, Australia, 6150
                            Kynan Feeney, 08 9428 8556      
Description: The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone
Contact: For more information contact clinical.trials@bms.com

Trial Name: A Phase I/IIa Study of the Efficacy and Safety of ASN-002 Alone or in Combination with 5-Fluoruracil (5-FU) in Adult Patients with Low-Risk Nodular Basal Cell Carcinoma (Gorlin Syndrome) (NCT02550678)
Location:    Central Brisbane Dermatology: Level 9, Silverton Place, 101 Wickham Terrace,

                            Brisbane QLD 4000, Dr Gregory Siller, 07 3831 4382
                     Q-Pharm Pty Limited: 300C Herston Road, Herston QLD 4006,       
                            Hilary Morrison, 07 3845 3657

                     St George Dermatology and Skin Cancer Centre, Kogarah, NSW, 2217
                            Sharyn Hutchinson, 02 9587 4277, clinicaltrials@stgeorgedermatology.com.au
                     Sinclair Dermatology, Melbourne, Victoria, 3002, Rodney Sinclair 03 9654 2426
                             sinclair@epworthdermatology.com.au
Description:
This research project is testing the safety and effectiveness (efficacy) of ASN-002, (an experimental treatment) alone or in combination with 5-Fluorouracil (5-FU), an anticancer chemotherapy drug. The study will also look at the changes in your BCC(s) over time, when ASN-002 alone or in-combination with 5-FU is administered directly into the BCC(s) by intra-tumoural injection. For more information, please click here
Contact: For more information contact clementleong@ascendbiopharma.com

Trial Name: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) (ACTRN12614000950662)
Location: Canberra Hospital, Canberra, Australian Capital Territory, Australia, 2606
                 Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia, 2310
                 Prince of Wales Hospital, Sydney, New South Wales, Australia, 2031
                 Princess Alexandra Hospital, Brisbane, Queensland, Australia, 4120
                 Ashford Cancer Centre Research, Adelaide, South Australia, Australia, 5037
                 Flinders Medical Centre, Adelaide, South Australia, Australia, 5042
                 Royal Hobart Hospital, Hobart, Tasmania, Australia, 7001
                 Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia, 3199
                 Border Medical Oncology, Wodonga, Victoria, Australia, 3690
                 Sir Charles Gairdner, Perth, Western Australia, Australia, 6009
Description:
 An open label randomised trial for adults with histologically confirmed measurable metastatic GIST who have received no other treatment for metastatic disease. The study aims to determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety in comparison to imatinib alone to warrant further evaluation as a first line treatment for metastatic GIST.
Contact:
ALT GIST Coordinator, 02 9562 5000, altgist@ctc.usyd.edu.au

Trial Name: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (NCT02899299)
Location:    Concord Repatriation General Hospital, Sydney, New South Wales, Australia, 2139,
                              Anthony Linton, +61 2976 77033
                    Birtinya, Queensland, Australia, 4575
                    Monash Medical Center Clayton, Victoria, Australia, 3168, Muhammad Alamgeer, +61 3992 88754
                    Cabrini Hospital Malvern, Victoria, Australia, 3144, Benjamin Brady, +61 3950 83421
                    Nedlands, Western Australia, Australia, 6009
Description:
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma

Trial Name: A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma (NCT02155647)
Locations:     Lismore Base Hospital, New South Wales
                       Royal North Shore Hospital, New South Wales

Description: This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).
Contact:        
Adam Boyce, 02 6629 4559, aboyce@oncnorthcoast.com.au
                       Alexander Guminski, 02 9911 7210, alexander.guminski@health.nsw.gov.au

Trial Name: A parallel group randomised, controlled, multi-centre phase II open label trial with two cohorts testing the combination of capecitabine and temozolomide (CAPTEM) and peptide receptor radionuclide therapy (PRRT) for the treatment of advanced pancreatic or midgut neuroendocrine tumours that are not suitable for surgery.  (ACTRN12615000909527)
Location: GI Cancer Institute @ Lifehouse, Level 6, 119-143 Missenden Road, Camperdown NSW 2050

Description: The CONTROL NETS study aims to determine the activity of capecitabine + temozolomide (CAPTEM)/peptide receptor radionuclide therapy (PRRT), alone and in combination, in both pancreatic neuroendocrine tumours (pNETS) and mid-gut neuroendocrine tumours (mNETS) patients. 
Contact:
 controlnets@ctc.usyd.edu.au

Trial Name: NABNEC - A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (ACTRN12616000958482)
Locations:       Royal North Shore Hospital, St Leonards, New South Wales
                         Westmead Hospital, Westmead, New South Wales
                         Calvary Mater Newcastle Hospital, Newcastle, New South Wales
                         Monash Medical Centre, Moorabbin, Victoria
                         Fiona Stanley Hospital, Murdoch, Western Australia
                         Royal Hobart Hospital, Hobart, Tasmania

Description: The primary purpose of this trial is to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide chemotherapy for the treatment of gastrointestinal neuroendocrine carcinomas (NECs)
Contact:
Dr Mustafa Khasraw nabnec@ctc.usyd.edu.au 
For further locations, additional information and contact details, please click here

Trial Name: InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease (ACTRN12616000061437)
Location: Flinders Medical Centre - Bedford Park, South Australia

Description: The purpose of the study is to compare two different chemotherapy regimens for the treatment of inoperable, locally recurrent, or metastatic anal cancer to demonstrate which is more effective and less toxic for patients with this disease. 
Contact:
Dr Amitesh C Roy - interAACT@ctc.usyd.edu.au
For further locations, additional information and contact details, please click here

Trial Name: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers (NCT01587703
Location: Clayton, Victoria, 3168

Description: This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration of GSK525762 in the following subjects: NMC, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), neuroblastoma (NB), castration resistant prostate cancer (CRPC), triple negative breast cancer (TNBC), estrogen receptor positive (ER positive) breast cancer, and MYCN driven solid tumor subjects. Part 2 of the study will explore the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of the recommended dose from the cohorts in Part 1. The study is now also upon to Gastrointestinal Stromal Tumour (GIST) patients.
Contact:
 arun.azad@monash.edu

Trial Name: AN OPEN-LABEL, MULTICENTRE, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK 1/2/3, ROS1, OR ALK GENE REARRANGEMENTS (NCT02568267)
Location: Border Medical Oncolgy Albury, New South Wales

Description: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Contact:
 dlong@bordermedonc.com.au
For further locations and contact details, please click here